Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 28, 2013; 19(48): 9377-9382
Published online Dec 28, 2013. doi: 10.3748/wjg.v19.i48.9377
Published online Dec 28, 2013. doi: 10.3748/wjg.v19.i48.9377
Table 3 Outcome of infants born to control mothers and tenofovir disoproxil fumarate-treated mothers n (%)
| Infant characteristics and outcomes | Infants of control group mothers (n= 23) | Infants of treated group mothers (n= 21) |
| Birth weight < 2500 g | 1 (4.3) | 1 (4.7) |
| Immunophrophylaxis failure | 2 (8.3) | 0 (0) |
| Anti-hepatitis B surface levels > 100 mIU/mL | 19 (82) | 20 (95) |
| Hypothyroidism | 0 (0) | 0 (0) |
| Phenylketonuria | 0 (0) | 0 (0) |
| Congenital hearing loss | 0 (0) | 0 (0) |
- Citation: Celen MK, Mert D, Ay M, Dal T, Kaya S, Yildirim N, Gulsun S, Barcin T, Kalkanli S, Dal MS, Ayaz C. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. World J Gastroenterol 2013; 19(48): 9377-9382
- URL: https://www.wjgnet.com/1007-9327/full/v19/i48/9377.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i48.9377